Results of bevacizumab biosimilar compared with RMP for the treatment of metastatic colorectal cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e14065
Abstract: Background: BEVZ92 has being developed as a proposed biosimilar approved reference medicine product (RMP). BEVZ92 has an identical amino acid sequence and highly similar physicochemical and in vitro functional properties to RMP. The aim of… read more here.
Keywords: compared rmp; treatment; results bevacizumab; biosimilar compared ... See more keywords
Matching-adjusted indirect comparison of tislelizumab plus lenvatinib versus sintilimab plus bevacizumab biosimilar as first-line treatment for unresectable hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2025 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2025.1594935
Abstract: Background Programmed cell death-1/programmed cell death-ligand 1 (PD-[L]1) inhibitors plus bevacizumab (or biosimilars) or tyrosine kinase inhibitors (TKIs) have been widely used for the first-line treatment of patients with unresectable hepatocellular carcinoma (uHCC). However, no… read more here.
Keywords: treatment; tislelizumab plus; plus lenvatinib; sintilimab plus ... See more keywords
Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1036906
Abstract: Background Bevacizumab has played an important role in the systemic treatment of patients with advanced non-small-cell lung cancer (NSCLC) without gene mutation. In recent years, bevacizumab biosimilar has received marketing approval based on the results… read more here.
Keywords: locally advanced; reference; bevacizumab; efficacy safety ... See more keywords
Sintilimab plus a bevacizumab biosimilar (IBI305) in advanced HCC with Child-Pugh A/B liver function: a real-world multicenter retrospective study
Sign Up to like & getrecommendations! Published in 2025 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2025.1681663
Abstract: Background Sintilimab plus a Bevacizumab biosimilar (IBI305) is an approved first-line regimen for unresectable hepatocellular carcinoma (uHCC) in China. However, data on its safety and efficacy in patients with impaired liver function remain limited. We… read more here.
Keywords: biosimilar ibi305; function; liver function; sintilimab plus ... See more keywords
Sintilimab Plus Bevacizumab Biosimilar Versus Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.778505
Abstract: Objective: The ORIENT-32 clinical trial revealed that sintilimab plus bevacizumab biosimilar significantly improved the median progression-free survival and median overall survival (OS) compared with sorafenib. This analysis evaluated the cost-effectiveness of sintilimab plus bevacizumab biosimilar… read more here.
Keywords: plus bevacizumab; first line; sintilimab plus; cost effectiveness ... See more keywords